Trials / Completed
CompletedNCT04782115
Evaluation of RC28-E Injection in Diabetic Macular Edema
Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Diabetic Macular Edema.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | intravitreal injection of RC28-E | a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF |
| BIOLOGICAL | Conbercept | KH902(Conbercept） |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
- First posted
- 2021-03-04
- Last updated
- 2023-12-18
Locations
37 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04782115. Inclusion in this directory is not an endorsement.